Invex Therapeutics Ltd
ASX:IXC

Watchlist Manager
Invex Therapeutics Ltd Logo
Invex Therapeutics Ltd
ASX:IXC
Watchlist
Price: 0.125 AUD 4.17% Market Closed
Market Cap: 9.4m AUD

Operating Margin
Invex Therapeutics Ltd

-103.3%
Current
-536%
Average
6%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-103.3%
=
Operating Profit
-476.9k
/
Revenue
461.5k

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
AU
Invex Therapeutics Ltd
ASX:IXC
9.4m AUD
-103%
US
Eli Lilly and Co
NYSE:LLY
1T USD
44%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
3%
US
Johnson & Johnson
NYSE:JNJ
498.9B USD
27%
CH
Roche Holding AG
SIX:ROG
261.4B CHF
34%
UK
AstraZeneca PLC
LSE:AZN
210.8B GBP
24%
CH
Novartis AG
SIX:NOVN
210.3B CHF
33%
US
Merck & Co Inc
NYSE:MRK
264.8B USD
38%
DK
Novo Nordisk A/S
CSE:NOVO B
1.5T DKK
42%
IE
Endo International PLC
LSE:0Y5F
213.9B USD
11%
US
Pfizer Inc
NYSE:PFE
143.2B USD
29%
No Stocks Found

Invex Therapeutics Ltd
Glance View

Market Cap
9.4m AUD
Industry
Pharmaceuticals

Invex Therapeutics Ltd. is a biopharmaceutical company, which engages in the research and development of treatment for neurological conditions resulting from raised intracranial pressure. The company is headquartered in Subiaco, Western Australia. The company went IPO on 2019-07-05. The firm is focused on the development and commercialisation of Presendin (Exenatide) for neurological conditions relating to raised intracranial pressure. The firm received written responses from the United States Food and Drug Administration (FDA) Division of Neurology relating to its proposed Phase III clinical trial design for Presendin in Idiopathic Intracranial Hypertension (IIH). Exenatide is a glucagon-like peptide-1 receptor agonist approved for the treatment of type II diabetes. The firm focuses on reformulating Exenatide to deliver it in a way that enables exploitation of its unknown ability to reduce cerebral spinal fluid secretion in the choroid plexus of the brain. The firm intends to progress expediently to clinical evaluation and undertake the registration of different formulations of Exenatide optimized to treat different neurological conditions.

IXC Intrinsic Value
HIDDEN
Show
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-103.3%
=
Operating Profit
-476.9k
/
Revenue
461.5k
What is the Operating Margin of Invex Therapeutics Ltd?

Based on Invex Therapeutics Ltd's most recent financial statements, the company has Operating Margin of -103.3%.

Back to Top